Putative antiviral effects of propofol in COVID-19

Wei, Penghui; Zheng, Qiang; Ye, Haotian; Lyu, Wenyuan; Yang, Jianjun

doi:10.1016/j.bja.2021.02.006

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, propofol, often used for intubation sedation in patients with COVID-19, exhibits direct anti-COVID-19 effects by inhibiting sigma-1 receptors in vitro. Propofol also indirectly suppresses inflammation and thrombosis formation (Wei et al 2021 ; Lucchetta et al 2020 ). The broad-spectrum antiemetic prochlorperazine has not yet been reported for SLE or COVID-19 treatment; however, its potential effects on common COVID-19 symptoms, such as nausea and vomiting, are evident.…”

Section: Discussionmentioning

confidence: 99%

Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk

Nian,

Mao,

et al. 2024

Mol Med

View full text Add to dashboard Cite

Background Studies have highlighted a possible crosstalk between the pathogeneses of COVID-19 and systemic lupus erythematosus (SLE); however, the interactive mechanisms remain unclear. We aimed to elucidate the impact of COVID-19 on SLE using clinical information and the underlying mechanisms of both diseases. Methods RNA-seq datasets were used to identify shared hub gene signatures between COVID-19 and SLE, while genome-wide association study datasets were used to delineate the interaction mechanisms of the key signaling pathways. Finally, single-cell RNA-seq datasets were used to determine the primary target cells expressing the shared hub genes and key signaling pathways. Results COVID-19 may affect patients with SLE through hematologic involvement and exacerbated inflammatory responses. We identified 14 shared hub genes between COVID-19 and SLE that were significantly associated with interferon (IFN)-I/II. We also screened and obtained four core transcription factors related to these hub genes, confirming the regulatory role of the IFN-I/II-mediated Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway on these hub genes. Further, SLE and COVID-19 can interact via IFN-I/II and IFN-I/II receptors, promoting the levels of monokines, including interleukin (IL)-6/10, tumor necrosis factor-α, and IFN-γ, and elevating the incidence rate and risk of cytokine release syndrome. Therefore, in SLE and COVID-19, both hub genes and core TFs are enriched within monocytes/macrophages. Conclusions The interaction between SLE and COVID-19 promotes the activation of the IFN-I/II-triggered JAK-STAT signaling pathway in monocytes/macrophages. These findings provide a new direction and rationale for diagnosing and treating patients with SLE–COVID-19 comorbidity.

show abstract

Section: Discussionmentioning

confidence: 99%

Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk

Nian,

Mao,

et al. 2024

Mol Med

View full text Add to dashboard Cite

show abstract

“…Propofol ACE2 may be upregulated when tissues are exposed to sedative concentrations (!10 mg ml À1 ) for >6 h. 7 Propofol might inhibit SARS-CoV-2 entry as suggested for hydroxychloroquine. 8 In addition, clinically relevant concentrations of propofol may have Sig-1R antagonistic properties. 7 Moreover, propofol has both antioxidant and antiinflammatory actions and may reduce systemic inflammation and exert organ protection in COVID-19.…”

Section: Intravenous Anaesthetic Agents and Sedativesmentioning

confidence: 99%

Anaesthesia-related drugs and SARS-CoV-2 infection

Hirota

Lambert

2021

British Journal of Anaesthesia

View full text Add to dashboard Cite

EditordAlthough there is extensive discussion of COVID anaesthesia management and infection control in the operating theatre, there are few articles examining whether perioperative anaesthesia-related drugs could affect COVID-19. Here, we discuss this possibility.SARS-CoV-2 binding sites (Fig. 1) Angiotensin converting enzyme 2 Angiotensin converting enzyme 2 (ACE2) is the best-known target cell receptor for SARS-CoV-2 internalisation. It is widely distributed in human cells and tissues and highly expressed in the small intestine, testes, kidneys, heart, thyroid, lungs, salivary glands, and adipose tissues, but not in the vocal folds, epiglottis, and trachea. 1 Sigma-1 receptor SARS-CoV-2 interacts with sigma receptors via non-structural protein 6 and coronavirus open reading frame (Orf) 9c proteins to infect cells. 2 Knockout and knockdown of sigma-1 receptor (Sig-1R), but not of Sig-2R, decreased SARS-CoV-2 replication. Modulation of Sig-1R may thus affect the early steps of viral endocytosis to change SARS-CoV-2 infection for immunologic enhancement. 3

show abstract

“…Propofol (2,6-diisopropylphenol) is a commonly used intravenous anesthetic and sedative agent administered during surgery and in intensive care units ( Wang et al, 2019 ). It is widely used as a first-line agent to sedate intubated and mechanically ventilated patients with coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome occurring during the COVID-19 pandemic ( Wei et al, 2021 ). Among anesthetic medications, propofol has most frequently been reported as a risk factor for urine discoloration ( Tucker and Perazella, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Pink Urine Syndrome Following Exposure to Propofol: A Rare, Impressive but Benign Complication

et al. 2021

Self Cite

View full text Add to dashboard Cite

Drug-induced changes in urine color induced by drugs may have clinical significance. Pink urine syndrome (PUS), which has been associated with urinary uric acid (UA) disorders, is most frequently reported in patients with morbid obesity undergoing gastric bypass surgery and/or from propofol anesthesia use in those who potentially have preexisting UA metabolism disorders. However, PUS has rarely occurred following exposure to propofol in non-obese patients, and literature on long-term follow-up after PUS is scarce. We report a case of PUS induced by propofol in a previously healthy non-obese woman after undergoing thoracoscopic wedge resection of pulmonary nodules under general anesthesia using propofol. The patient suddenly developed pink urine 4 h after surgery. A pink sediment rapidly precipitated at the bottom of the test tube following centrifugation of the urine. Amorphous, colorless UA-like crystals were identified under a polarizing microscope. The diagnosis of PUS was confirmed by examining the urinary UA concentration. The patient recovered and as followed-up for 1 month, during which she did not experience any urinary complications. To our knowledge, this is the first report to describe in detail a case of PUS caused by propofol in a non-obese patient with follow-up. PUS is usually benign and can resolve by rapidly on administering lactated Ringer’s solution; however, the potential risk of urinary complications, particularly UA lithiasis, should be fully realized.

show abstract

Putative antiviral effects of propofol in COVID-19

Cited by 4 publications

References 15 publications

Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk

Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk

Anaesthesia-related drugs and SARS-CoV-2 infection

Case Report: Pink Urine Syndrome Following Exposure to Propofol: A Rare, Impressive but Benign Complication

Contact Info

Product

Resources

About